Works matching DE "ZOLEDRONIC acid"

Results: 1329

Bilateral atypical femur fracture in a patient with breast cancer taking zoledronic acid and denosumab: A case report.

Published in:

Modern Rheumatology Case Reports, 2025, v. 9, n. 1, p. 41, doi. 10.1093/mrcr/rxae059

By:

Kazuhiko Hashimoto;
Tomohiko Ito;
Yuto Yamagishi;
Koji Goto

Publication type:

Article

Early and multiple doses of zoledronate mitigates rebound bone loss following withdrawal of receptor activator of nuclear factor kappa-B ligand inhibition.

Published in:

Journal of Bone & Mineral Research, 2025, v. 40, n. 3, p. 413, doi. 10.1093/jbmr/zjaf008

By:

Kim, Albert S;
Taylor, Victoria E;
Castro-Martinez, Ariel;
Dhakal, Suraj;
Zamerli, Amjad;
Mohanty, Sindhu T;
Xiao, Ya;
Simic, Marija K;
Pantalone, Alyssa;
Chu, Julian;
Cheng, Tegan L;
Croucher, Peter I;
Center, Jacqueline R;
Girgis, Christian M;
McDonald, Michelle M

Publication type:

Article

Bone-Modifying Agents as Adjuvant Therapy for Early-Stage Breast Cancer.

Published in:

Oncology (08909091), 2012, v. 26, n. 10, p. 955

By:

Figueroa-Magalhães, Maria Cristina;
Miller, Robert S.

Publication type:

Article

基层医院重度骨质疏松症病人唑来膦酸静脉给药不良反应观察及护理.

Published in:

Chinese Nursing Research, 2023, v. 37, n. 17, p. 3226, doi. 10.12102/j.issn.1009-6493.2023.17.035

By:

孔祥双;
郭光霞;
王连英;
赵翠伶;
付佐娣;
李玉凤

Publication type:

Article

Denosumab versus bisphosphonates for the treatment of bone metastases from solid tumors: a systematic review.

Published in:

2019

By:

Matuoka, Jessica Y.;
Kahn, James G.;
Secoli, Silvia R.

Publication type:

journal article

A Rare Case of Malignant Phyllodes Tumor of Breast Metastatic to the Skeletal Muscle.

Published in:

Indian Journal of Surgery, 2018, v. 80, n. 4, p. 385, doi. 10.1007/s12262-017-1693-0

By:

Mate, Pooja Uttam;
Madholia, Vikas;
Choudhary, Akansha

Publication type:

Article

Zoledronic acid overcomes chemoresistance by sensitizing cancer stem cells to apoptosis.

Published in:

Biotechnic & Histochemistry, 2018, v. 93, n. 2, p. 77, doi. 10.1080/10520295.2017.1387286

By:

Rouhrazi, H;
Turgan, N;
Oktem, G

Publication type:

Article

Combining radiation therapy with zoledronate for the treatment of osteo‐invasive feline oral squamous cell carcinoma.

Published in:

Veterinary & Comparative Oncology, 2022, v. 20, n. 4, p. 788, doi. 10.1111/vco.12830

By:

Lundberg, Alycen P.;
Tran Hoang, Christine;
Billhymer, Audrey;
Selting, Kim A.

Publication type:

Article

Combined zoledronic acid and meloxicam reduced bone loss and tumour growth in an orthotopic mouse model of bone-invasive oral squamous cell carcinoma.

Published in:

Veterinary & Comparative Oncology, 2015, v. 13, n. 3, p. 203, doi. 10.1111/vco.12037

By:

Martin, C. K.;
Dirksen, W. P.;
Carlton, M. M.;
Lanigan, L. G.;
Pillai, S. P.;
Werbeck, J. L.;
Simmons, J. K.;
Hildreth, B. E.;
London, C. A.;
Toribio, R. E.;
Rosol, T. J.

Publication type:

Article

Elevated baseline CTX levels predict enhanced therapeutic efficacy of zoledronic acid in augmenting lumbar spine bone mineral density among Chinese osteoporosis patients.

Published in:

Osteoporosis International, 2025, v. 36, n. 4, p. 707, doi. 10.1007/s00198-025-07448-7

By:

Zhang, Qing;
Gao, Wenxue;
Xu, Xiaojuan;
Cui, Ran;
Su, Bin

Publication type:

Article

Early administration of zoledronic acid after hip fracture.

Published in:

2025

By:

McCarroll, Kevin;
Mahon, James;
Lannon, Rosaleen;
Carroll, Aisling;
Fitzpatrick, Donal

Publication type:

Letter

Changing trends in bisphosphonate therapy: a twenty-five-year surveillance in a single US integrated healthcare system.

Published in:

Osteoporosis International, 2025, v. 36, n. 4, p. 741, doi. 10.1007/s00198-024-07372-2

By:

Lo, Joan C.;
Chandra, Malini;
Khan, Mehreen M.;
Barzilay, Joshua;
Carbone, Laura D.;
Ott, Susan M.;
Adler, Robert A.;
Schousboe, John T.;
Garcia, Elisha A.;
Low, Deborah;
Hui, Rita L.

Publication type:

Article

The clinical trial landscape of anti-RANKL agents for osteoporosis: current status and future directions.

Published in:

Osteoporosis International, 2025, v. 36, n. 3, p. 573, doi. 10.1007/s00198-025-07389-1

By:

Li, Xin;
Cheng, Lin

Publication type:

Article

Clinical experience with denosumab discontinuation.

Published in:

Osteoporosis International, 2025, v. 36, n. 3, p. 435, doi. 10.1007/s00198-024-07351-7

By:

Laursen, Natasha;
Sølling, Anne Sophie;
Harsløf, Torben;
Langdahl, Bente

Publication type:

Article

Assessing the impact of the 5 Nations Consensus Paper on IV Zolendronate administration post-hip fracture in older patients: experience from a UK teaching hospital.

Published in:

2025

By:

Soopramanien, J.;
Wakefield, A.;
Marshall, L.;
Nightingale, J.;
Sahota, O.

Publication type:

Letter

Transient osteoporosis of the hip following discontinuation of denosumab and switch to alendronate treatment.

Published in:

2024

By:

Makras, Polyzois;
Yavropoulou, Maria P.;
Anastasilakis, Athanasios D.;
Papatheodorou, Athanasios;
Tekedis, Christos;
Papapoulos, Socrates E.

Publication type:

Letter to the Editor

Association of prior treatment with nitrogen-containing bisphosphonates on outcomes of COVID-19 positive patients.

Published in:

Osteoporosis International, 2024, v. 35, n. 1, p. 181, doi. 10.1007/s00198-023-06912-6

By:

Lee, R.H.;
Curtis, J.;
Drake, M.T.;
Bobo Tanner IV, S.;
Lenert, L.;
Schmader, K.;
Pieper, C.;
North, R.;
Lyles, K.W.

Publication type:

Article

Twenty-four months of follow-up in women with rebound-associated vertebral fractures after discontinuation of denosumab: a single-centre case series.

Published in:

Osteoporosis International, 2024, v. 35, n. 1, p. 165, doi. 10.1007/s00198-023-06894-5

By:

Clifton Goldney, Dolores;
Pelegrin, Carolina;
Jerkovich, Fernando;
Longobardi, Vanesa;
Gonzalez Rodriguez, Elena;
Zanchetta, María Belén

Publication type:

Article

Correction to: Comparison of anti-fracture effectiveness of zoledronate, ibandronate and alendronate versus denosumab in a registry-based cohort study.

Published in:

2023

By:

Everts-Graber, Judith;
Bonel, Harald;
Lehmann, Daniel;
Gahl, Brigitta;
Häuselmann, HansJörg;
Studer, Ueli;
Ziswiler, Hans-Rudolf;
Reichenbach, Stephan;
Lehmann, Thomas

Publication type:

Correction Notice

Comparison of anti-fracture effectiveness of zoledronate, ibandronate and alendronate versus denosumab in a registry-based cohort study.

Published in:

Osteoporosis International, 2023, v. 34, n. 11, p. 1961, doi. 10.1007/s00198-023-06863-y

By:

Everts-Graber, Judith;
Bonel, Harald;
Lehmann, Daniel;
Gahl, Brigitta;
Häuselmann, HansJörg;
Studer, Ueli;
Ziswiler, Hans-Rudolf;
Reichenbach, Stephan;
Lehmann, Thomas

Publication type:

Article

Atypical femoral fracture after denosumab for the treatment of osteoporosis in bisphosphonate naïve patients: two further cases.

Published in:

2023

By:

Fitzpatrick, D.;
Seebah, S.;
Lannon, R.;
Mc Carroll, K.

Publication type:

Letter to the Editor

Zoledronic acid–induced severe lymphopenia.

Published in:

Osteoporosis International, 2023, v. 34, n. 9, p. 1653, doi. 10.1007/s00198-023-06831-6

By:

Karpuz, Savaş

Publication type:

Article

Zoledronic acid after spinal cord injury mitigates losses in proximal femoral strength independent of ambulation ability.

Published in:

Osteoporosis International, 2023, v. 34, n. 9, p. 1637, doi. 10.1007/s00198-023-06811-w

By:

Crack, Laura E.;
Haider, Ifaz T.;
Simonian, Narina;
Barroso, Joana;
Gabel, Leigh;
Schnitzer, Thomas J.;
Edwards, W. Brent

Publication type:

Article

The impact of acute-phase reaction on mortality and re-fracture after zoledronic acid in hospitalized elderly osteoporotic fracture patients.

Published in:

Osteoporosis International, 2023, v. 34, n. 9, p. 1613, doi. 10.1007/s00198-023-06803-w

By:

Lu, K.;
Wu, Y.-m.;
Shi, Q.;
Gong, Y.-q.;
Zhang, T.;
Li, C.

Publication type:

Article

Changes in RANKL and TRAcP 5b after discontinuation of denosumab suggest RANKL mediated formation of osteoclasts results in the increased bone resorption.

Published in:

Osteoporosis International, 2023, v. 34, n. 3, p. 599, doi. 10.1007/s00198-022-06651-0

By:

Sølling, Anne Sophie;
Harsløf, Torben;
Jørgensen, Niklas Rye;
Langdahl, Bente

Publication type:

Article

Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study.

Published in:

Osteoporosis International, 2023, v. 34, n. 3, p. 573, doi. 10.1007/s00198-022-06648-9

By:

Tutaworn, Teerapat;
Nieves, Jeri W.;
Wang, Zhaorui;
Levin, Justin E.;
Yoo, Jae E.;
Lane, Joseph M.

Publication type:

Article

Discontinuation of denosumab in men with prostate cancer.

Published in:

Osteoporosis International, 2023, v. 34, n. 2, p. 291, doi. 10.1007/s00198-022-06610-9

By:

Sølling, Anne Sophie;
Harsløf, Torben;
Brockstedt, Helle Kongsbak;
Langdahl, Bente

Publication type:

Article

Renal safety of zoledronic acid for osteoporosis in adults 75 years and older.

Published in:

Osteoporosis International, 2022, v. 33, n. 11, p. 2417, doi. 10.1007/s00198-022-06499-4

By:

Fixen, Cy W.;
Fixen, Danielle R.

Publication type:

Article

Predicting the acute-phase response fever risk in bisphosphonate-naive osteoporotic patients receiving their first dose of zoledronate.

Published in:

Osteoporosis International, 2022, v. 33, n. 11, p. 2381, doi. 10.1007/s00198-022-06493-w

By:

Lu, Ke;
Shi, Qin;
Gong, Ya-qin;
Shao, Jia-wei;
Li, Chong

Publication type:

Article

Comment on "Rebound hypercalcemia post-denosumab cessation in metastatic breast cancer": Waxing-Waning Serum Calcium following Denosumab use in a patient with Polyostotic Paget's Disease of Bone.

Published in:

2022

By:

Pal, Rimesh;
Bhadada, Sanjay Kumar

Publication type:

Letter

Safety of zoledronate in older patients at high risk of fracture with reduced renal function.

Published in:

2022

By:

Sahota, A.;
Barbary, R.;
Cameron, M.;
Stewart, A.-M.;
Sahota, O.

Publication type:

Letter

Rebound hypercalcemia post-denosumab cessation in metastatic breast cancer.

Published in:

Osteoporosis International, 2022, v. 33, n. 7, p. 1625, doi. 10.1007/s00198-022-06369-z

By:

Wang, R.;
Renouf, D. A.

Publication type:

Article

The clinical utility of TRACP-5b to monitor anti-resorptive treatments of osteoporosis.

Published in:

Osteoporosis International, 2022, v. 33, n. 6, p. 1357, doi. 10.1007/s00198-022-06311-3

By:

Gossiel, F.;
Ugur, A.;
Peel, N. F. A.;
Walsh, J. S.;
Eastell, R.

Publication type:

Article

Evaluation of estimated glomerular function (eGFR) versus creatinine clearance (CrCl) to predict acute kidney injury when using zoledronate for the treatment of osteoporosis.

Published in:

Osteoporosis International, 2022, v. 33, n. 3, p. 737, doi. 10.1007/s00198-021-06160-6

By:

Schini, M.;
Peel, N.;
Toronjo-Urquiza, L.;
Thomas, E.;
Salam, S.;
Khwaja, A.;
Eastell, R.;
Walsh, J. S.

Publication type:

Article

Zoledronic acid and bone health in older adults with cognitive impairment.

Published in:

Osteoporosis International, 2022, v. 33, n. 1, p. 293, doi. 10.1007/s00198-021-06063-6

By:

Churilla, B.M.;
Perera, S.;
Greenspan, S.L.;
Resnick, N.M.;
Kotlarczyk, M.P.

Publication type:

Article

Cost-effectiveness of 3 versus 6 years of zoledronic acid treatment before bisphosphonate holiday for women with osteoporosis.

Published in:

Osteoporosis International, 2022, v. 33, n. 1, p. 229, doi. 10.1007/s00198-021-06010-5

By:

Nayak, S.;
Greenspan, S. L.

Publication type:

Article

Bisphosphonate holidays: using cost-effectiveness analysis for the "yes, but" questions.

Published in:

2021

By:

Colón-Emeric, C.S.;
Lee, R.H.

Publication type:

Editorial

Hypercalcemia in non-Hodgkin's lymphoma due to cosecretion of PTHrP and 1,25-dihydroxyvitamin D.

Published in:

Osteoporosis International, 2021, v. 32, n. 12, p. 2587, doi. 10.1007/s00198-021-06054-7

By:

Gonciulea, A.R.;
Wang, Y.;
Bikle, D.D.;
Sellmeyer, D.E.

Publication type:

Article

Diffuse adverse cutaneous reactions induced by zoledronic acid administration: a case report: Eruptions cutanées diffuses induites par l'administration de l'acide zolédronique.

Published in:

Osteoporosis International, 2021, v. 32, n. 12, p. 2583, doi. 10.1007/s00198-021-06021-2

By:

Nassar, Kawtar;
Janani, Saadia

Publication type:

Article

Response to: "Zoledronate-induced acute anterior uveitis: a three-case report and brief review of literature".

Published in:

Osteoporosis International, 2021, v. 32, n. 10, p. 2139, doi. 10.1007/s00198-021-06092-1

By:

Samalia, Priya;
Niederer, Rachael

Publication type:

Article

Simulated effects of early menopausal bone mineral density preservation on long-term fracture risk: a feasibility study.

Published in:

Osteoporosis International, 2021, v. 32, n. 7, p. 1313, doi. 10.1007/s00198-021-05826-5

By:

Billington, E. O.;
Leslie, W. D.;
Brown, J. P.;
Prior, J. C.;
Morin, S. N.;
Kovacs, C. S.;
Kaiser, S. M.;
Lentle, B. C.;
Anastassiades, T.;
Towheed, T.;
Kline, G. A.

Publication type:

Article

Efficacy of annual zoledronic acid in initial percutaneous kyphoplasty patients with osteoporotic vertebral compression fractures: a 3-year follow-up study.

Published in:

Osteoporosis International, 2021, v. 32, n. 7, p. 1429, doi. 10.1007/s00198-020-05816-z

By:

Lu, K.;
Yin, Y.;
Li, C.;
Jin, Y.;
Shan, H.-q.

Publication type:

Article

Zoledronic acid reduces the rate of clinical fractures after surgical repair of a hip fracture regardless of the Pretreatment bone mineral density.

Published in:

Osteoporosis International, 2021, v. 32, n. 6, p. 1217, doi. 10.1007/s00198-021-05923-5

By:

Lyles, K.W.;
Bauer, D.C.;
Colon-Emeric, C.S.;
Pieper, C.F.;
Cummings, S.R.;
Black, D.M.

Publication type:

Article

Multiple bilateral hip fractures in a patient with dyskeratosis congenita caused by a novel mutation in the PARN gene.

Published in:

Osteoporosis International, 2021, v. 32, n. 6, p. 1227, doi. 10.1007/s00198-020-05758-6

By:

Belaya, Z.;
Golounina, O.;
Nikitin, A.;
Tarbaeva, N.;
Pigarova, E.;
Mamedova, E.;
Vorontsova, M.;
Shafieva, I.;
Demina, I.;
Van Hul, W.

Publication type:

Article

Addition of dexamethasone to manage acute phase responses following initial zoledronic acid infusion.

Published in:

Osteoporosis International, 2021, v. 32, n. 4, p. 663, doi. 10.1007/s00198-020-05653-0

By:

Chen, F.-P.;
Fu, T.-S.;
Lin, Y.-C.;
Lin, Y.-J.

Publication type:

Article

Cost-effectiveness of buffered soluble alendronate 70 mg effervescent tablet for the treatment of postmenopausal women with osteoporosis in Italy.

Published in:

Osteoporosis International, 2021, v. 32, n. 3, p. 595, doi. 10.1007/s00198-020-05802-5

By:

Hiligsmann, M.;
Maggi, S.;
Veronese, N.;
Sartori, L.;
Reginster, J.-Y.

Publication type:

Article

Comparative effectiveness of denosumab, teriparatide, and zoledronic acid among frail older adults: a retrospective cohort study.

Published in:

Osteoporosis International, 2021, v. 32, n. 3, p. 565, doi. 10.1007/s00198-020-05732-2

By:

Zullo, A. R.;
Lee, Y.;
Lary, C.;
Daiello, L. A.;
Kiel, D. P.;
Berry, S. D.

Publication type:

Article

Therapeutic efficacy of zoledronic acid combined with calcitriol in elderly patients receiving total hip arthroplasty or hemiarthroplasty for osteoporotic femoral neck fracture.

Published in:

Osteoporosis International, 2021, v. 32, n. 3, p. 559, doi. 10.1007/s00198-020-05637-0

By:

Zhu, K.;
Zhang, J.;
Zhang, C.;
Zhao, Z.;
Gao, J.;
Li, X.;
Xia, X.;
Xu, X.;
Zhang, T.;
Guan, J.

Publication type:

Article

Functional electrical stimulation (FES)–assisted rowing combined with zoledronic acid, but not alone, preserves distal femur strength and stiffness in people with chronic spinal cord injury.

Published in:

Osteoporosis International, 2021, v. 32, n. 3, p. 549, doi. 10.1007/s00198-020-05610-x

By:

Fang, Y.;
Morse, L.R.;
Nguyen, N.;
Battaglino, R.A.;
Goldstein, R.F.;
Troy, K.L.

Publication type:

Article

A single dose of zoledronate preserves bone mineral density for up to 2 years after a second course of romosozumab.

Published in:

Osteoporosis International, 2020, v. 31, n. 11, p. 2231, doi. 10.1007/s00198-020-05502-0

By:

McClung, M. R.;
Bolognese, M. A.;
Brown, J. P.;
Reginster, J.-Y.;
Langdahl, B. L.;
Maddox, J.;
Shi, Y.;
Rojeski, M.;
Meisner, P. D.;
Grauer, A.

Publication type:

Article